Quick hit

From this morning’s WSJ — “On Feb. 10, Valeant Pharmaceuticals International Inc. bought the rights to a pair of life-saving heart drugs. The same day, their list prices rose by 525% and 212%.” According to the article, this is an MO for several drug companies.  Interestingly, the patents on these drugs expired years ago, but they currently have no generic competition. That may or may not change. But in any event,  cost curve up. 

Leave a Reply

Your email address will not be published.